{
    "clinical_study": {
        "@rank": "77300", 
        "acronym": "EYEGUARD\u2122-B", 
        "arm_group": [
            {
                "arm_group_label": "Gevokizumab", 
                "arm_group_type": "Experimental", 
                "description": "Solution for subcutaneous injection, Dose 1"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Solution for subcutaneous injection, placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to demonstrate the superiority of gevokizumab as compared to\n      placebo on top of current standard of care in reducing the risk of Beh\u00e7et's disease uveitis\n      exacerbations"
        }, 
        "brief_title": "Efficacy of Gevokizumab in the Treatment of Patients With Beh\u00e7et's Disease Uveitis (EYEGUARD\u2122-B)", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Behcet's Uveitis", 
        "condition_browse": {
            "mesh_term": [
                "Behcet Syndrome", 
                "Uveitis", 
                "Chorioretinitis"
            ]
        }, 
        "detailed_description": {
            "textblock": "A randomized, double-masked, placebo-controlled study of the efficacy of gevokizumab in the\n      treatment of patients with Beh\u00e7et's disease uveitis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Beh\u00e7et's disease diagnosis fulfilling the International Study Group Classification\n             Criteria.\n\n          -  History of Beh\u00e7et's disease uveitis with ocular involvement of the posterior segment.\n\n          -  Patients with a stable background treatment of oral corticosteroid and at least one\n             immunosuppressive drug.\n\n          -  Male or female, age \u226518 (or legal age of majority in the country) at selection\n\n          -  For subjects with reproductive potential, a willingness to use highly effective\n             contraceptive measures\n\n        Exclusion Criteria:\n\n          -  Infectious uveitis, uveitis due to causes other than Beh\u00e7et's disease.\n\n          -  Monocular vision\n\n          -  Presence of severe cataract or severe posterior capsular opacification.\n\n          -  Contraindication to mydriasis or presence of posterior synechiae.\n\n          -  Active TB disease.\n\n          -  History of severe allergic or anaphylactic reactions to monoclonal antibodies\n\n          -  History of malignancy within 5 years prior to Selection.\n\n        Other protocol-defined inclusion/exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "110", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01965145", 
            "org_study_id": "CL3-78989-002", 
            "secondary_id": [
                "2012-001125-27", 
                "U1111-1135-1411"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Gevokizumab", 
                "description": "Sterile solution administered subcutaneously", 
                "intervention_name": "Gevokizumab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Sterile solution administered subcutaneously", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 17, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "120-752"
                }, 
                "name": "Yonsei University Severance Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-masked, Placebo-controlled Study of the Efficacy of Gevokizumab in the Treatment of Patients With Beh\u00e7et's Disease Uveitis", 
        "overall_contact": {
            "email": "clinicaltrials@servier.com", 
            "last_name": "IRIS"
        }, 
        "overall_official": {
            "affiliation": "Yonsei University Severance Hospital", 
            "last_name": "Sung Chul LEE, Pr", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "number of days", 
            "measure": "Time to first acute ocular exacerbation", 
            "safety_issue": "No", 
            "time_frame": "up to 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01965145"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Servier", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Servier", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}